Emanuele Crupi

Skin Toxic Effects and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma

Importance Skin toxic effects are a common early adverse event of enfortumab vedotin plus pembrolizumab (EVP) therapy, but its association with clinical outcomes in patients receiving first-line therapy remains uncertain. Objective To evaluate the association between treatment-em...